TY - JOUR
T1 - Artemether-lumefantrine
T2 - An oral antimalarial for uncomplicated malaria in children
AU - Adjei, George O.
AU - Goka, Bamenla Q.
AU - Binka, Fred
AU - Al Kurtzhals, Jorgen
PY - 2009/8
Y1 - 2009/8
N2 - Artemether-lumefantrine (AL; Coartem®, Riamet®) is the first fixed-dose artemisinin combination therapy (ACT) regimen to be manufactured under Good Manufacturing Practice conditions, and is the most widely adopted ACT regimen used in malaria control programs. AL is approved for the treatment of uncomplicated malaria in adults, children and infants, and as treatment of uncomplicated malaria in nonimmune travelers returning from malarious areas. AL is efficacious for treating uncomplicated malaria in children and the frequency of associated adverse events is not higher than other available ACT regimens. In this review, available evidence on efficacy and safety of AL in the treatment of uncomplicated malaria, with emphasis on children where appropriate, and focusing on characteristics that are potentially important for malaria control policy decisions, are presented and discussed.
AB - Artemether-lumefantrine (AL; Coartem®, Riamet®) is the first fixed-dose artemisinin combination therapy (ACT) regimen to be manufactured under Good Manufacturing Practice conditions, and is the most widely adopted ACT regimen used in malaria control programs. AL is approved for the treatment of uncomplicated malaria in adults, children and infants, and as treatment of uncomplicated malaria in nonimmune travelers returning from malarious areas. AL is efficacious for treating uncomplicated malaria in children and the frequency of associated adverse events is not higher than other available ACT regimens. In this review, available evidence on efficacy and safety of AL in the treatment of uncomplicated malaria, with emphasis on children where appropriate, and focusing on characteristics that are potentially important for malaria control policy decisions, are presented and discussed.
KW - Artemether-lumefantrine
KW - Artemisinin combination therapy
KW - Children
KW - Uncomplicated malaria
UR - http://www.scopus.com/inward/record.url?scp=70350462395&partnerID=8YFLogxK
U2 - 10.1586/ERI.09.53
DO - 10.1586/ERI.09.53
M3 - Review article
C2 - 19681693
AN - SCOPUS:70350462395
SN - 1478-7210
VL - 7
SP - 669
EP - 681
JO - Expert Review of Anti-Infective Therapy
JF - Expert Review of Anti-Infective Therapy
IS - 6
ER -
